In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Cabaletta Bio (CABA – Research Report), with a price target of $12.00. The company’s shares closed today at $7.73.
According to TipRanks, Livshits is a 5-star analyst with an average return of 25.4% and a 37.84% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, PDS Biotechnology, and Krystal Biotech.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cabaletta Bio with a $14.60 average price target, representing an 88.87% upside. In a report released on March 17, H.C. Wainwright also reiterated a Buy rating on the stock with a $15.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on Cabaletta Bio’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $11.43 million. In comparison, last year the company had a GAAP net loss of $13.89 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in 2017 and is headquartered in Philadelphia, PA.
Read More on CABA:
- 3 Stocks to Buy Today, 3/17/2023, According to Top Analysts
- Cabaletta Bio price target raised to $15 from $11 at H.C. Wainwright
- Cabaletta Bio reports Q4 EPS (52c), consensus (45c)
- Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Cabaletta Bio to Present at the Cowen 43rd Annual Health Care Conference
